TP53 and prostate carcinoma: While metastatic progression of prostate cancer has been linked to many somatic mutations and epigenetic alterations (PTEN, p53, Myc, etc.), more recent work determined that alterations in Myc occur in some of the earliest phases of disease, that is, in tumor-initiating cells (Koh et al., 2010).